US 2026/0201038 A1 · ANTIBODY SPECIFICALLY BINDING TO B7-H3

Abstract

The present disclosure relates to an anti-B7-H3 antibody or an antigen-binding fragment thereof, which binds to a specific epitope located within the amino acid sequence of a domain of B7-H3. The antibody (i) specifically binds to various types of cancer cell lines expressing B7-H3, demonstrating T cell-mediated cancer cell-killing effect, and (ii) binds to epitopes in both humans and mice, thus allowing for effective evaluation of anticancer effect in preclinical trials when developed into a therapeutic antibody.

Claims20

Dependent claims

An anti-B7-H3 antibody or an antigen-binding fragment thereof, which specifically binds to an epitope located within the amino acid sequence of a domain of B7-H3, selected from a group consisting of an Ig-like-V-type 1 sequence of SEQ ID NO:

36, an Ig-like-V-type 2 sequence of SEQ ID NO:
38 and an Ig-like-V-type sequence of SEQ ID NO:
40.

An anti-B7-H3 antibody or an antigen-binding fragment thereof binding specifically to B7-H3, wherein

the anti-B7-H3 antibody or the antigen-binding fragment thereof comprises light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR2 and CDR3, wherein the light chain CDR1, CDR2 and CDR3 are represented by SEQ ID NOS:
3, 4 and 5, respectively, and the heavy chain CDR1, CDR2 and CDR3 are represented by SEQ ID NOS:
6, 7 and 8, respectively.

Dependencies are inferred from the claim text.

Antibody specifically binding to b7-h3

Life of this patent

Antibody specifically binding to b7-h3

Life of this patent

Abstract

Claims20